CClinicalTrials.gg
TerminatedNCT03252119Updated Jul 24, 2019

High Flow Oxygen Therapy vs Standard Care in Infants With Viral Bronchiolitis

An interventional study of High flow humidified oxygen therapy in Bronchiolitis, Viral, sponsored by Chris Hani Baragwanath Academic Hospital. Terminated at 1 site in South Africa. Open to participants aged 1 Month to 2 Years. Per ClinicalTrials.gov, last updated 2019-07-24.

Sponsored by Chris Hani Baragwanath Academic Hospital · Not applicable, Interventional, and Treatment

Why this study was terminated
High flow oxygen therapy became available as standard care
Phase
Not applicable
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
1 Month to 2 Years
Sex
All
01

Study summary

A randomized control trial of 130 infants admitted to the paediatric high care admission ward will be enrolled, and randomized to either "high flow humidified oxygen" or "standard therapy".

Read the detailed description

A randomized control trial of 130 infants admitted to the paediatric high care admission ward will be enrolled. Infants between 1 month and 2 years of age who fulfill criteria for enrollment shall be considered eligible. Informed consent from parents or legal guardians shall be obtained. Infants shall be randomized to either "standard therapy" or "high flow humidified oxygen". Measurements of heart rate, respiratory rate, work of breathing (Tal score and WCAS), oxygen saturation and oxygen requirements shall be recorded.

02

Conditions studied

  • Bronchiolitis, Viral
03

Who can participate

Ages eligible
1 Month to 2 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Clinical diagnosis of viral bronchiolitis
  • Not requiring intubation and ventilation
  • Admitted to high care unit
  • With moderate/severe respiratory distress (Tal score >6)
  • Saturations \<92% in room air

Exclusion criteria

Exclusion Criteria:

  • congenital cardiac disease
  • presence of multiorgan failure/multisystemic disease
  • previously ventilated
  • craniofacial abnormalities
  • nasal pathology
  • decreased level of consciousness
  • Ex-prem \<34 weeks
  • Possible impending respiratory failure
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • No intervention
    standard therapy group

    standard treatment of viral bronchiolitis with low flow oxygen.

  • Experimental
    high flow humidified oxygen group

    treatment of viral bronchiolitis with high flow humidified oxygen therapy.

    Device: High flow humidified oxygen therapy

Interventions

  • DeviceHigh flow humidified oxygen therapy

    application of high flow humidified oxygen therapy at 2l/kg/min

05

What researchers measure

Primary outcomes

  1. Effect of high flow humidified oxygen therapy on work of breathing

    Respiratory rate (n/min)

    Time frame: during first 5 days post enrollment

  2. Effect of high flow humidified oxygen therapy on work of breathing

    Use of accessory muscles of respiration (present /not)

    Time frame: first 5 days post enrollment

  3. Effect of high flow humidified oxygen therapy on blood oxygen saturations

    Saturation of oxygen (% saturation) as measured by pulse oximeter

    Time frame: first 5 days post enrollment

  4. Effect of high flow humidified oxygen therapy on heart rate

    Pulse (n/min) measured by ECG monitor

    Time frame: first 5 days post enrollment

Secondary outcomes

  1. Proportion of patients requiring intubation and ventilation

    number of patients (N) getting intubated

    Time frame: from time of enrollment to end of hospital stay (up to 6 months)

  2. Length of hospital stay

    days (N) spent in hospital

    Time frame: from time of enrollment to end of hospital stay (up to 6 months)

06

Study locations

1 site
  • Chris Hani Baragwanath Academic Hospital
    Johannesburg, Gauteng, South Africa
07

References and documents

Individual participant data

Plan to share: No — No plan to share data wit other researchers

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03252119
Lead sponsor
Chris Hani Baragwanath Academic Hospital
Responsible party
Susan Murphy (Specialist Intensivist, Chris Hani Baragwanath Academic Hospital) — Principal investigator
First posted
Aug 17, 2017
Start date
Jun 1, 2017
Primary completion
Aug 31, 2018
Completion
Aug 31, 2018
Last update
Jul 24, 2019

Study contacts

Susan M Murphy, FCPaed (SA)
principal investigator · University of the Witwatersrand, Johannesburg

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion